País: Irlanda
Idioma: anglès
Font: HPRA (Health Products Regulatory Authority)
Progesterone
LTT Pharma Limited
G03DA; G03DA04
Progesterone
8 percent weight/weight
Vaginal gel
Intravaginal application
15 units
Product subject to prescription which may not be renewed (A)
Central Pharma (Contract Packaging) Ltd
Sex hormones
Pregnen (4) derivatives; progesterone
Infertility due to inadequate luteal phase
Authorised
2015-03-06
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. Your medicine is called Crinone 8% w/w progesterone vaginal gel but will be referred to as Crinone throughout the leaflet. WHAT IS IN THIS LEAFLET: What Crinone is and what it is used for What you need to know before you use Crinone How to use Crinone Possible side effects How to store Crinone Contents of the pack and other information WHAT CRINONE IS AND WHAT IT IS USED FOR Crinone® 8% w/w Progesterone Vaginal Gel contains progesterone and is used for the treatment of infertility due to a deficiency of the female hormone progesterone during the menstrual cycle. During the menstrual cycle, an egg develops in the ovary during the first 14 days. This is called the follicular phase of the menstrual cycle. Ovulation then occurs and leaves a corpus luteum in the ovary. This is called the luteal phase of the menstrual cycle. This corpus luteum produces progesterone for 12-16 days which helps to thicken and maintain the lining of the uterus (womb) ready for a fertilised egg. If fertilisation of the egg does not occur, the progesterone level falls and the lining of the uterus is shed (menstruation). If the egg is fertilised and the embryo implants in the lining of the uterus, the corpus luteum continues to produce progesterone to support the pregnancy until the embryos placenta takes over at 10 weeks into the pregnancy. In some women the progesterone produced in the luteal phase is absent or insufficient to maintain the lining of the uterus and support early development Llegiu el document complet
Health Products Regulatory Authority 22 October 2018 CRN008N50 Page 1 of 3 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Crinone 8% w/w progesterone vaginal gel 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Ingredient Mg/dose % w/w Progesterone 90 8.0 Excipients with known effect: contains sorbic acid 0.08% w/w (0.9mg/1.125g dose) For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Vaginal gel _Product imported from the Czech Republic:_ White to off white gel contained in a white plastic applicator. 4 CLINICAL PARTICULARS As per PA2286/001/001 5 PHARMACOLOGICAL PROPERTIES As per PA2286/001/001 6 PHARMACEUTICAL PARTICULARS 6.1 LIST OF EXCIPIENTS Glycerol Light Liquid Paraffin Hydrogenated Palm Oil Carbomer 974P Sorbic acid Polycarbophil Sodium hydroxide Purified water Health Products Regulatory Authority 22 October 2018 CRN008N50 Page 2 of 3 6.2 INCOMPATIBILITIES No incompatibilities were found with the usual contraceptive devices. 6.3 SHELF LIFE The shelf life expiry date for this product shall be the date shown on the blister and outer package of the product on the market in the country of origin. 6.4 SPECIAL PRECAUTIONS FOR STORAGE Do not store above 25°C. 6.5 NATURE AND CONTENTS OF CONTAINER A single use, one piece, white polyethylene applicator with a twist-off top, designed for intravaginal application. Each applicator contains 1.45g of gel and delivers 1.125g of gel. Each one is wrapped up and sealed in a paper/aluminium/polyethylene foil overwrap. The applicators are packed in cardboard boxes containing 15 units of Crinone 8% progesterone vaginal gel. Not all pack sizes may be marketed. 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL No special requirements. 7 PARALLEL PRODUCT AUTHORISATION HOLDER LTT Pharma Limited Unit 18 Oxleasow Road East Moons Moat Redditch, Worcestershire B98 0RE United Kingdom 8 PARALLEL PRODUCT AUTHORISATION NUMBER PPA1562/146/001 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Health Products Regulatory Authority 22 October 2018 CRN008 Llegiu el document complet